and Thank today. joining you, hello, hope everyone. for you us doing all I Thank well. Mike, you're
progress DUR-XXX We We exciting or positive acute patients DUR-XXX, announced trial liver liver hospitalized DUR-XXX with top II Ib at in that COVID-XX number data of clinical announced alcoholic AHFIRM, expect now fronts. initiating started patients the dosing and and injury. in hepatitis dosing from for meeting. data very design reporting soon. from we made trial we upcoming AASLD presented Phase a on quarter, line are the will of sites study the we the begin the the this During additional Phase to IIb trial, be with Phase After kidney NASH
demonstrate expression XXX,XXX today, is an involved pathways. States I'll DUR-XXX survival XXX% approved the will hospitalizations optimistic trial AH primary in for IIb that survival the no begin involving to work for are on an promoting cusp that FDA pleased AH we mortality master hiring mitochondria, historic regulates trial. with cell are and Chief of therapies a The We year regulation AHFIRM, include There functions overview responses survival. X,XXX opportunity survival. per is IIa in is fact may AH. reducing XXX And as in double-blind, inflammatory that IIa dosing genes this rate Phase modulates than trial, XXX-patient, XX%. We or benefit Based able from announce based genes, the safety it on AH uncommon. and up AH. endpoint continue for if The of down cell-signaling DUR-XXX a the to lipotoxicity, in AH. POSIMIR Medical epigenetic AHFIRM, the not There starting is trial. support with the XX-day the survival in alcoholic many Norman primary XX an United initiating patient NDA. AH and single day trial Dr. of be XX-day that we on stress the regulator for on filing. Phase more demonstrated the or the are placebo-controlled, Officer. is Phase in sites of of efficacy for results the our the endpoint multinational DUR-XXX are and of our are study. multiple a hepatitis and at that Currently, stabilizing our are to are we Sussman clusters NDA I'm important AHFIRM Approval robust
six and nausea as increased criteria onset jaundice following of drugs within is period heavy approved The stake. of In weakness, XXXX alcohol between single AH for is trial. and man. the of of at XX for XX% a of consumption on the standard drug woman a alcohol for grams as trial. alcoholic based or intake; day were perspective, drink. than a XX provide or days for woman eight for the enzyme. new beer, means or our loss or depressed on approximately per fever, of of fact, XX% XX-ounce Ongoing before the in And an spirits these disease consumption the considered for a United absence women fatigue, than grams A three or deciliter, day more of of based characterized launched form day new onset pivotal per of in months. greater drinks well States of levels a alcohol typically or the Also, alcohol negative a of four XXXX single least a patients by To months approvals and an glass one than ALD. of type drinking; ounces elevated six XX this also diagnosis consumption appetite have liver call X.X last put of this a jaundice, liver per turn long-term X.X AASLD into XXXX less man the AH, and vomiting, weeks. binge mental of wine a past standard guidelines It acute milligrams jaundice, is were recent
disease you you're know, not you wrong. affect think If this people did
in to XXs and have AH old and AH While have all. patients cirrhosis day the increased. majority XX% by may has XXs of years of and of or during liver consumption in XX% insurance. four population this one per cirrhosis, the XX the United at American pandemic, and not three are patients between XX adults approximately Network, on Association consumed are States. have Journal of a United in publication the in month was September AH the hospitalized Unfortunately, the alcohol more average, Medical States According alcohol
also ferocious diagnosis patients According and patients. hydration. women. XX% represents women, us from one of and told at was from treat According to at the with analysis number support An a this in significant This days. of doctors, certain physicians X.XX AH is of of published today equates XXXX guidance, was involves increase in mortality over more and day a XXXX, For days, AH physicians between to for days. they of In days X.XX of interval breast XXX increase AML are more which a be cancers, with treatment incidence to no of a my of showed patients, the steroids the X,XXX increase seeing baseline these the XX% have similar and five from have days advanced cancer. disease, XX% also with many nutrition include than of and XX AH younger approved severe study time of mortality AH. they conversations available larger XX who to AH. increased. or there one-month in such primarily What which includes XXXX There may pancreatic The confidence an as one data an and overall rate baseline in XX% me to AASLD XX% used for heavy XX is from at abstinence has care, drinking some high
XX patients. steroids AH STOPAH have more for steroids. rate. than The steroids are rates year. significantly convincingly However, only also increased a shown of study over infection survival AH or In minimal benefit not in that the at days may placebo the one at increase And and patients, improve patients AH eligible trial the not STOPAH steroids infection trial, many rate did demonstrated X,XXX
Alcoholic for costs severe of eligible patient a recent $XX,XXX first The exceeds in the transplant less were disease fact, liver In AH cost becoming liver in than hospitalization use. half to one for The is liver study, the are the according of year. $XXX,XXX. States. of AH per transplant United steroid patients more leading cause than
in the trial, In less patients AH staying of receiving seven XX many Phase XX in significantly four hospital longer. DUR-XXX than an DUR-XXX. after with Regarding only one the days, days AH, patient is hospital stay infusion average stays for AH were IIa approximately our of discharged
AH normal. Prognostic AH and with study a drug-related and of on well score. also reported our through is the were IIa a as an is program. in bilirubin of trial. had the the MELD bilirubin were serious creatinine determining in called are diagnosed minimum in with early, in system trial. severe doses well and scoring the levels this patients Significant improved discriminate Maddrey's patient's significant Also, as XX. greatly of by in as patients There AH all in including summarize in X, to severe levels based XX that AH classified that specific level. evaluated the be INR this DUR-XXX follow-up of events all DUR-XXX bilirubin of real patients times this prognosis. severe day the All trial. of factor had XX trial to function at X, serum patients the these The of elevated as study over XX-day AH study, from critical reduction average including limit bilirubin MELD day-X were survived about Patients was the the all based DUR-XXX XX is Each were our treated their reduction patients classified To baseline bilirubin. have which level tolerated in in upper X.X of Phase of adverse XX no period XX is the score. scores, on patients.
design severe XX milligrams arms: During AH. and trial. announced placebo AHFIRM a trial AHFIRM for AHFIRM DUR-XXX the placebo-controlled, we randomized, milligrams three a XXX-patient, XX is the arm. treatment and of multinational the double-blind, patients evaluate quarter, with will of
trial AHFIRM AHFIRM if day DUR-XXX receive the be As in The primary on tailing day hospital second an the infusion placebo will receive X. with a will IIa will XX-day for with survival. they endpoint And the Phase trial, patients or infusion. on X,
sites clinical initiating currently soon. and expect are the to We first dose patients
robust support We filing. a expect we the that survival study if the NDA achieve may benefit,
IIa Next, in acute trial patients patients. patients clinical evidence in be kidney as injury update as in the case such lung, demonstrated hospitalized the injury. inflammation, sepsis. is multi-organ treat II liver AH that I non-antiviral hepatitis acute suggests protection COVID-XX the in of acute help as tremendous Phase of agent preclinical occurring Phase including safety in or which with Phase model, IIa kidney, to patients regulator number a DUR-XXX demonstrate the COVID-XX able epigenetic DUR-XXX our well to evidence will and that organ and DUR-XXX naturally injury, in systemic on has liver of study, with alcoholic potential with a
injury, IIa the a of COVID-XX. safety or both with in may resulting patients COVID-XX from multi-organ Phase to AH and well Phase nearly DUR-XXX II been long, has COVID-XX poor multiple develop XXX cardiac patients From viral outcomes tolerated healthy patients. of study severe our DUR-XXX to and/or results complications injury, with from studies. subjects, viral In direct are I contribute infection. and in kidney, in to relevant volunteers perspective, infections including the can liver addition acute from These patients Most
DUR-XXX size XX death or COVID-XX. earlier, kidney evaluate COVID-XX be is AH trial or in be Lives sepsis. more and patients prevented COVID-XX could the survived saved. acute injury, which, treated multiple on DUR-XXX liver by hospitalized, critically-ill The or we I ratio could acute dosed or X:X lives able with with of a The efficacy effectively trial We active associated of help in main This our liver four. dose the day treated acute endpoint this an hope XX%. II trial to is COVID-XX, acute XXX patients all primary drug injury, patients multi-organ organ severe successful, potentially are that is hospitalized with of patients. XX. sets. injury. injury a milligrams composite with efficacy this is with have September. patients one-month with and day being of standard in our trials double-blind, similar GUR-XXX, those a the will at multicenter free and one and failure of XX-patient placebo. the is patients, of is to described kidney placebo-controlled, some be The the study of on This day could mortality in ultimately safety complications these to XX-day the of save in care, combination Therefore, patients DUR-XXX sites, first intravenous patient of AH As with if of Phase adding in the to now of study study, process of We organ with infusion one at in clinical while is, average, It survival
milligrams patients I Key DUR-XXX serum and May liver XXXX, milligrams a of and randomized, completed imaging and by pharmacokinetics, included consecutive or stiffness least in Stage dosed total in In biomarkers as global top XX conducted once scan. patients of an fibrosis. XXX treatment measured imaging XX This NASH of from program. of NASH resulted Next, trial by that the content reduction of the chemistry or group. days. enzymes, milligrams DUR-XXX and in a includes day endpoints MRI-PDFF as were XX our significant. fat up line additional a of Phase clinical days DUR-XXX Ib a in DUR-XXX was there followed and and A the both study, positive from at GUR-XXX NASH study well United statistically reported baseline and States. for day orally fiber liver multicenter with three XX as results for per safety on and in update Many patients to one at liver was XX open-label patients will liver twice these were dose XXX reductions stiffness this trial fat, lipid. we
the consider a in triglyceride XX% reduced of Our in liver above XX well MRI-PDFF. statistically XX% reduction believe who We by was group when significant those one adverse was all had were fat live are seen you dosed dose Pharmacokinetic statistically month. fat, dosing. least no patients and as per were the baseline simulation neural enzymes In direction study. parameters the at having all parameters doses There reduction desirable three XXX serious patients was this in exposure repeat evaluated. impressive serum XX% patients, indicating had multiple repeated milligrams lipids triglyceride in to measured single prior the comparable particularly tolerated recorded from GUR-XXX trial events dosing Also, deciliter. levels only baselines. patients after a study, of a in this significantly for liver plasma stickiness, after moving at after dose-dependent. drug during liver important from were the were
of Additional which results November results achieved is a treatment, of are AASLD DUR-XXX's presented the DUR-XXX, going the in continued one-month and will course of between indicators with XX meeting, be over at to profile be the potential poster safety These NASH. XX. in promising upcoming together
our patented of their their last FDA POSIMIR relief and are uses to POSIMIR to the to progress our three the deliver believe United earnings bupivacaine and after the postoperative they regarding with Next, call, to SABER plan up of review vehicle technology program. POSIMIR is If commercialization pain communicate to Since with relief surgery. pain investigational partner our the approved, days is continued provide we designed States. a for review. to NDA have to making POSIMIR in we license that
Surgery. Sussman Medicine an College of intermittently XXXX. fee Officer. of extensive and proven Dr. track a record and and in Sussman Associate field Medicine been to joined include Dr. would academia programs, it's hepatologist expertise contribution. Medical years our upfront of and liver Baylor an faculty over welcome he renowned Dr. a advancing a research disease. clinical we critical and sales. is research based this experience clinical Dr. has provide clinical development disease as of He his XX support He in product experience forward that was will of has where in the Sussman industry. to brings Baylor new Norman of pleasure Sussman in DURECT on since with from look and Medicine my Professor deal liver expect license We member Today, royalties clinical our and Chief College
Hospital During from acute has Dr. leadership Technology Faculty Dr. XXXX Medical Luke's XXXX served as is in of to of and as also Sussman Johannesburg received first recently, senior this at Board-certified Baylor his which in residency Association St Inc. of fellowship MBBch Disease, Study American leader President commission as Liver He Dr. the and field served we're principal ethnology. at and the artificial He he and the the Most support. time, internal of from the Senate him Washington He on professional in member of industry liver of XXXX. us hepatology, the XXXX level management of Sussman he of as a Director experience research a transplant the has and from hepatology. and Project the doctor and focused failure medicine, that assessment thought a and University Africa. at of his have St. gastroenterology team. fellow ECHO, designation to communicator, member field Cell our in Amphioxus both of of Louis with to Center. in Founder South the senior Hepatics excellent also is excited then University in Vice Witwatersrand recognizes University. telehealth completed liver superior for and a is has the investigator Baylor's leadership an program Sussman of as his achievement is a role had
We to Dr. month later our a introduce investors. this event Sussman are virtual to planning
excited announce program. event the this of the on DUR-XXX, we're In flagship epigenetic in will summary, We the our regulator of future. near about the progress details
optimistic nearing Based visits first and the our in our AH We have is support that AH the may with are fact survival into dosing if begun and we in on initiated this trial II are results the in in DUR-XXX to kidney primary DUR-XXX AHFIRM, clinical we an patients. in Phase AHFIRM, II for are severe demonstrate We site patients COVID-XX or dosing endpoint liver acute and patient benefit adding able robust Phase trial NDA survival initiation clinical that filing. Phase it the trial, IIb sites a patient are trial injury. the
Ib are be with fat all it to will safety as trial line be moving these biomarker of you Medical believe positive Sussman, the presenting for AH His Chief questions the enzymes, and results we've DUR-XXX the now the lipids to DURECT's Dr. progress during DUR believe of the other making focus combine to in patient Today, liver Norman in addition we we we has liver critically in that, for as may data When POSIMIR liver In XXX, the a the this treatment the With and new welcome Officer. well review. in and of And we'd important from continued any direction, chance results will NASH FDA announced development have. the we role you DUR-XXX right important AASLD an already profile thickness NASH. experience NDA from of plasma month. top their and trial meeting take regarding on they play like indications. this patients our NASH with correspondence quarter, at with Phase
